The potential therapeutic applications of RNAi were realized almost immediately after the phenomenon was first described; over the years, developers have gradually progressed their proprietary drug candidates with cautious optimism Roots Analysis is pleased to announce the publication of its recent study, titled, “RNAi Therapeutics Market (2nd Edition), 2019 - 2030: Focus on siRNA, miRNA, shRNA and DNA.” The “RNAi Therapeutics Market (2nd Edition), 2019-2030: Focus On siRNA, miRNA, shRNA and DNA” report features an extensive study of the current market landscape and future opportunities associated with RNAi therapeutics.The study also features a detailed analysis of key drivers and trends within this evolving market.Amongst other elements, the report includes:A detailed assessment of the current market landscape of drug developers engaged in the development of RNAi therapeutics.A competitiveness analysis of key players engaged in this domain, evaluating their respective product portfolios, type of RNAi molecule, target therapeutic areas, company size and year of establishmentA detailed analysis of more than 70 completed, ongoing and planned clinical studies of RNAi therapeutics.A detailed analysis of various patents that have been filed / granted related to RNAi therapeutics, since 2014An analysis of the partnerships that have been established in this domain, in the recent past.An analysis of the investments made at various stages of development in companies engaged in this domain.An analysis of the key promotional strategies that have been adopted by developers of marketed oligonucleotide therapeutics, namely Defitelio®, Exondys® and Onpattro®.Detailed profiles of RNAi Therapeutics that are in the late stage clinical developmentA detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Key Therapeutic AreasOncological disordersInfectious diseasesGenetic disordersOphthalmic disordersHepatic disordersRespiratory disordersType of RNAi moleculesiRNAmiRNAshRNAsshRNADNARoute of administrationSubcutaneousIntravenousIntradermalIntravitrealOralIntramuscularKey geographical regionsNorth AmericaEuropeAsia Pacific and the Rest of the worldLeading Player Key companies covered in the reportQuark PharmaceuticalsAlnylam PharmaceuticalsDicerna PharmaceuticalsSouzhou Ribo Life SciencesOlix PharmaceuticalsSirnaomicsAriz Precision MedicineArrowhead PharmaceuticalsGradalisBenitec Biopharma For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.htmlOther Recent OfferingsGene Therapy Market (3rd Edition), 2019-2030Global T-Cell (CAR-T, TCR and TIL) Therapy Market (4th Edition), 2019-2030Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]  
Multiplex Assays Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings with data Tables for historical and forecast years represented with Charts & Graphs spread through 350 Pages with easy to understand detailed analysis.The study highlights detailed assessment of the Market and display Multiplex Assays market sizing trend by revenue & volume (if applicable), expert opinions, current growth factors, facts, and industry validated market development data.Global multiplex assays market is expected to reach a healthy CAGR of 7.5% in the forecast period of 2019 to 2026.This is applicable for identification and estimation of analytes for heart disease, autoimmunity and allergy, cancer, and many other conditions.It is one of the easiest way for detection for the problems related to cardiovascular and others and with this company has added one more product in their product portfolio for serving it to their customer in market.In August 2017, Quanterix Corporation announced expansion for its single molecule array, or Simoa, technology platform portfolio by launching the new Quanterix SR-Plex benchtop instrument., MESO SCALE DIAGNOSTICS, LLC., QIAGEN, PerkinElmer Inc. , Illumina, Inc. , AGENA BIOSCIENCE, INC. , Olink , Randox Laboratories Ltd., Bio-Techne.Is it possible to add specific country or region of interest?Currently, research report gives special attention and focus on following regions: Asia-Pacific, South America, North America, Europe and & Middle East & Africa3) Can Market be broken down by different set of application and types?Additional Multiplex Assays Market segmentation / Market breakdown is possible subject to data availability, feasibility and depending upon timeline and toughness of survey.
2
Researchers at NASA and in Japan have found HMT — a key ingredient for life — trapped inside an asteroid. This chemical is used in building other organic materials, including some of the molecules which drive the mechanisms of life. Life on Earth is based on organic materials, built on carbon and hydrogen. These chemicals often also contain oxygen, nitrogen, and other elements. Three different carbon-rich meteorites were found to contain a prebiotic organic molecule called hexamethylenetetramine (also called hexamine, or HMT). This chemical, used to treat urinary infections as well as in the manufacture of blasting caps, is thought to… This story continues at The Next Web
7
Overview:The recent report by Market Research Future (MRFR) predicts the global Anti-Venom Market value will be expanding with a healthy CAGR of 6.5% over the forecast period (2017–2023).Biotechnology, as well as the healthcare industry, is noting a considerable demand from developing nations globally.Moreover, violation of forest lands for housing and agricultural needs has gotten humans close to poisonous animals and insects, thereby increasing the prevalence of venomous bites.In addition, the prevalence of snake bites, scorpion bites, as well as other animal or insect bites like fish stings is an additional factor playing a major role in the anti-venom market growth.Various research and development (R) activities taking place continuously that provide advanced drugs and standard treatment for poisonous insect bite further uplifts the market position of anti-venom.This is yet another driver responsible for the growth of the global anti-venoms market.In contrast, the high cost of anti-venom due to the high production cost in a few regions could hamper the growth of the anti-venom market.However, the rapid development of the economic conditions around the world is creating massive opportunities for the expansion of the anti-venom market.The contribution of the developing countries of Asia Pacific as well as the Middle East coupled with the growing population and increasing capita income will foster the growth of the market.SegmentationThe global anti-venom market is segmented on the basis of type, type of species, mode of action, product type, and end user.The global anti-venom market, by type, is categorized into polyvalent heterologous antivenom, monovalent heterologous antivenom, homologous antivenom, and small molecule anti-toxins.By species type, the global anti-venom market is segmented into snakes, scorpions, spiders, and others.
 To order this 750+ page report, please visit this link Key InclusionsA detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics.Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, focus area and type of biologics.A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired company.An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.In addition, it provides information on the technology advancements related to biomanufacturing.A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research.The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia).An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on a various relevant parameter, such as target patient population, dosing frequency and dose strength of the abovementioned products.A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:Commonly Outsourced Business OperationsActive Pharmaceutical Ingredients (API)Finished Dosage Formulations (FDF)Types of Expression SystemMammalianMicrobialOthersCompany SizeSmallMid-SizedLarge and Very LargeScale of OperationPreclinicalClinicalCommercialKey Geographical Region North AmericaEuropeAsia-Pacific To request sample pages, please visit this link Key Questions AnsweredWho are the key manufacturers (industry / non-industry) of cell-based therapies, across the world?What is the global demand for biologics-based therapies?What are the major recent developments (such as partnerships and expansions) in this industry?What kind of partnership models are commonly adopted by stakeholders in this domain?What is the current, installed contract manufacturing capacity for biologics?How is the current and future market opportunity likely to be distributed across key market segments?
 Owing to the ever-increasing number of start-ups that are involved in R of novel biologics, there is an enormous opportunity for the CMOs in this domain.It is worth emphasizing that, since 2000, more than 115 new CMOs have been established in order to serve to the growing demand for novel biologics that have specific manufacturing requirements.The contemporary contract services market features a mix of large and small-sized CMOs and is characterized by multiple mergers and acquisitions as stakeholders strive to broaden their respective service portfolios.This has enabled several CMOs to offer end-to-end services, ranging from drug development, including preliminary R, preclinical and clinical trials, to commercial scale production and regulatory filings To order this 750+ page report, which features 200+ figures and 250+ tables, please visit this link The USD 13.9 billion (by 2030) financial opportunity within the biopharmaceutical manufacturing market has been analyzed across the following segments:Commonly Outsourced Business OperationsActive Pharmaceutical Ingredients (API)Finished Dosage Formulations (FDF)Types of Expression SystemMammalianMicrobialOthersCompany SizeSmallMid-SizedLarge and Very LargeScale of OperationPreclinicalClinicalCommercialKey Geographical Region North AmericaEuropeAsia-PacificRest of the World  The Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030. report features the following companies, which we identified to be key players in this domain: 3P BiopharmaceuticalsAbzenaAlbany Molecular ResearchBioVectraBioXcellence (Boehringer Ingelheim)CelonicCharles River LaboratoriesChemPartnerCobra BiologicsCordenPharmaCytovance BiologicsGE HealthcareGoodwin BiotechnologyGrand River Aseptic ManufacturingIDT BiologikaKBI BioPharmaKemwell BiopharmaLFB BiomanufacturingMeridian Life SciencePatheonPfizer CentreOnePX'TherapeuticsSamsung BioLogicsSanofi, CEPiAThermo Fisher ScientificVetter Pharma International  Table of Contents  Preface 2.Executive Summary Introduction Competitive Landscape Biopharmaceutical Contract Manufacturing in North America Biopharmaceutical Contract Manufacturing in Europe Biopharmaceutical Contract Manufacturing in Asia Pacific And the Rest of The World Biopharmaceutical Contract Manufacturing in Asia Pacific And the Rest of The World Case Study: Outsourcing of Biosimilars Case Study: Comparison of Small Molecule and Large Molecule Drugs / Therapies  Case Study on In-House Manufacturing Collaborations Recent Developments Capacity Analysis  Demand Analysis  Market Forecast  SWOT Analysis  Future of The Biopharmaceutical CMO Market  Survey Analysis  Interview Transcripts  Appendix 1: List of Non-Industry Players  Appendix 1: List of Non-Industry Players  Appendix 3: List of Companies and Organizations To purchase a copy, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html Contact Details Gaurav Chaudhary+1 (415) 800 [email protected]    
 Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages Roots Analysis is pleased to announce the publication of its recent study, titled,  “Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.”  The report features an extensive study on the contract service providers within the biopharmaceutical industry.The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs.Amongst other elements, the report includes:A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters.Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biologics.A detailed discussion on the key enablers in this domain, including certain niche product classes, which are likely to have a significant impact on the growth of the contract services market.A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics.A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework.A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Commonly Outsourced Business OperationsActive Pharmaceutical Ingredients (API)Finished Dosage Formulations (FDF)Types of Expression SystemMammalianMicrobialOthersCompany SizeSmallMid-SizedLarge and Very LargeScale of OperationPreclinicalClinicalCommercialKey Geographical Region North AmericaEuropeAsia-PacificRest of the World  The report also features detailed transcripts of discussions held with the following experts:Astrid Brammer, Senior Manager Business Development, Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)Birgit Schwab, Senior Manager Strategic Marketing, Rentschler BiotechnologieChristian Bailly, Director of CDMO, Pierre FabreClaire Otjes, Assistant Marketing Manager, Batavia BiosciencesDavid C Cunningham, Director Corporate Development, Goodwin BiotechnologyDietmar Katinger, Chief Executive Officer, Polymun ScientificDenis Angioletti, Chief Commercial Officer, Cerbios-PharmaJeffrey Hung, Chief Commercial Officer, Vigene BiosciencesKevin Daley, Director Pharmaceuticals, NovasepMark Wright, Site Head, Grangemouth, Piramal HealthcareNicolas Grandchamp, R Leader, GEG TechRaquel Fortunato, Chief Executive Officer, GenIbet BiopharmaceuticalsSebastian Schuck, Head of Business Development, Wacker BiotechStephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth BiotechnologiesTatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactoryTim Oldham, Chief Executive Officer, Cell Therapies Key companies covered in the report3P BiopharmaceuticalsAbzenaAlbany Molecular ResearchBioVectraBioXcellence (Boehringer Ingelheim)CelonicCharles River LaboratoriesChemPartnerCobra BiologicsCordenPharmaCytovance BiologicsGE HealthcareGoodwin BiotechnologyGrand River Aseptic ManufacturingIDT BiologikaKBI BioPharmaKemwell BiopharmaLFB BiomanufacturingMeridian Life SciencePatheonPfizer CentreOnePX'TherapeuticsSamsung BioLogicsSanofi, CEPiAThermo Fisher ScientificVetter Pharma International For more information please click on the following link:Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030 Other Recent OfferingsCell Therapy Manufacturing Market (3rd Edition), 2019-2030Antibody Contract Manufacturing Market, 2020-2030China Biopharmaceutical Contract Manufacturing Market, 2020-2030Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]
In recent years, the concept of STING pathway targeting therapeutics has generated a lot of enthusiasm within the medical science community.The growing popularity of this therapeutic technique has not only garnered the interest of several medical researchers (reflected in the increasing volume of scientific literature (1,000+ articles published since 2015) on this subject), but also industry stakeholders focused on drug development (evident in the growing number of clinical trials and the grants awarded for STING focused projects in the recent past).To order this 310+ page report, which features 170+ figures and 200+ tables, please visit this link The USD 2.8 billion (by 2030) financial opportunity within the STING pathway targeting technologies market has been analysed across the following segments:Types of PaymentUpfront PaymentsMilestone Payments Type of STING ModulatorAgonistAntagonist Key Therapeutic Area(s)Oncological DisordersInflammatory DisordersInfectious DiseasesOthers Route of AdministrationIntratumoralIntravenousOralSubcutaneousOthers Type of MoleculeNon-nucleotideCyclic DinucleotideLive BiotherapeuticsOncolytic PeptidesSynthetic PeptidesOthers Key Geographical RegionsNorth AmericaEuropeAsia-Pacific  The STING Pathway targeting Therapeutics and Technologies, 2020-2030 report features the following companies, which we identified to be key players in this domain: Aduro BiotechBristol Myers SquibbEisaiGlaxoSmithKlineImmuneSensor TherapeuticsMerckNoxopharmSpring Bank PharmaceuticalsSynlogic Table of Contents  Preface 2.Executive Summary Introduction STING Pathway Targeting Therapeutics: Current Market Landscape STING Pathway Targeting Technologies: Current Market landscape Company Profiles Academic Grant Analysis STING Related Initiatives of Big Pharmaceutical Players Start-up Health Indexing Publication Analysis Partnerships and Collaborations Funding and Investment Analysis Market Sizing and Opportunity Analysis Executive Insights  Concluding Remarks  Appendix 1: Tabulated Data  Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected]  
To order this detailed 310+ page report, please visit this link  Key Inclusions A detailed assessment of the current market landscape of therapeutics targeting STING pathway, based on several parameters, such as type of STING modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, biologics and others), phase of development (discovery, preclinical and clinical), target therapeutic area(s), type of therapy (monotherapy and combination therapy), route of administration (intratumoral, intravenous and others), and line of treatment (last line, second line or greater and first line or greater).The chapter also features an analysis of the developer landscape (including information on year of establishment, company size, geography and most active players).Further the chapter includes an analysis on the clinical trials focused on STING, along with information on parameters, such as recruitment status, study design and clinical endpoints.A detailed chapter highlighting various technology platforms that are being actively used for the development of STING modulators and analysis based on several parameters, such as type of modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, live biotherapeutics, nanoparticles and synthetic peptides), and analysis based on technology developer landscape (including information on year of establishment, company size and geography).Elaborate profiles of key players that are engaged in the development of therapeutics targeting STING pathway (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, recent developments and an informed future outlook.Additionally, each drug profile features information on the type of drug, route of administration, target indications and current status of development.Tabulated profiles of industry players (shortlisted on the basis of the antagonist in pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, key members of the executive team and recent developments), along with descriptions of their respective drug candidates.A study on various grants that have been awarded to research institutes engaged in projects related to STING pathway, during the period 2015 - Q1 2020, based on multiple parameters, such as number of grants awarded, amount awarded, funding institute, support period, funding mechanism, type of grant application, grant activity code, most popular NIH department, type of recipient organization, regional distribution, most popular recipient organization(s), prominent project leader(s) and study section.It also includes an analysis of on grant attractiveness.An analysis of big pharma players engaged in the development of therapeutics targeting STING pathway, based on several parameters, such as portfolio diversity, type of molecule, phase of development, therapeutic area(s), type of therapy and route of administration.In addition, the chapter features a benchmarking analysis of the aforementioned players.An analysis of the start-ups / small players (established in the last ten years, less than 50 employees) engaged in the development of therapeutics targeting STING pathway, based on several relevant parameters, such as portfolio diversity, type of molecule, phase of development, therapeutic area, funding received, number of investors, type of funding, partnership activity, number of patents filed, grants received, and start-up health indexing.A detailed publication analysis of more than 300 peer-reviewed, scientific articles that have been published during the period 2019 - Q1 2020, highlighting the research focus within the industry.
Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals Roots Analysis is pleased to announce the publication of its recent study, titled “Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030” report to its list of offerings.The report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration.In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs.Amongst other elements, the report features the following:A detailed assessment of the current market landscape of commercially available and clinical-stage biologics that are designed for delivery via the subcutaneous routeA case study on leading subcutaneous biologics (in terms of revenues generated), featuring details on mechanism of action, development history, annual sales, technology platform (if available), and a comparison of their intravenous and subcutaneous formulations (if applicable).An assessment of the various subcutaneous formulation technologies along with information on developers, type of pharmacological molecule, route of administration, mechanisms of action and primary advantage(s).An insightful three-dimensional comparison of the subcutaneous formulation technology developers, based on pipeline strength, supplier power of the developer and primary advantages offered by their respective technologies.Elaborate profiles of key technology developers, featuring a brief overview of the company, its technology portfolio, product portfolio, financial information (if available), recent developments and an informed future outlook.An analysis of collaborations and partnership agreements inked by the subcutaneous formulation technology developers since 2011An in-depth review of the most advanced and popular subcutaneous drug delivery systems, including large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implantsA comprehensive product competitiveness analysis of subcutaneous large volume wearable injectors, subcutaneous autoinjectors, subcutaneous needle-free injectors and pre-filled syringesA discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry's evolution, under a comprehensive SWOT frameworkA detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):Phase of developmentApprovedPre-registration & Phase IIIPhase II & Phase II/III Type of moleculeCell and gene therapiesMonoclonal antibodiesProteinsPeptides (recombinant)VaccinesOthers Target therapeutic areaAutoimmune disordersBlood disordersBone disordersGenetic disordersMetabolic disordersNeurological disordersOncological disordersRespiratory disordersOthers Type of drug delivery systemLarge volume wearable injectorsAutoinjectorsPrefilled syringesNeedle-free injectorsDrug reconstitution systems Revenues from licensing dealsUpfront paymentsMilestone payments Key geographical regionsNorth AmericaEuropeAsia PacificRest of the World Transcripts of interviews held with the following senior level representatives of stakeholder companiesDeborah Bitterfield (Founder and Chief Executive Officer, Lindy Biosciences)Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies)Steve Prestrelski (Founder and Chief Scientific Officer, Xeris Pharmaceuticals), Hong Qi (Vice President, Product Development, Xeris Pharmaceuticals) and Scott Coleman (Senior Scientist, Formulation, Xeris Pharmaceuticals)David Daily (Co-Founder and Chief Executive Officer, DALI Medical Devices)Michael Reilly (Co-Founder and Chief Executive Officer and Co-Founder, Excelse Bio)Poonam R Velagaleti (Co-Founder, i-novion)Michael Hooven (Chief Executive Officer, Enable Injections)Frederic Ors (Chief Executive Officer, Immunovaccine Technologies)Patrick Anquetil (Chief Executive Officer, Portal Instruments)Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services) and Graham Reynolds (Vice President and General Manager, Global Biologics, West Pharmaceutical Services)David Heuzé (Communication Leader, MedinCell) Key companies covered in the reportAdociaAjinomoto Bio-Pharma ServicesArecorAlteogenAscendis PharmaAvadel PharmaceuticalsCamurusCreative BioMartCreative BiolabsDURECTEagle PharmaceuticalsHalozyme TherapeuticsMedinCellXeris PharmaceuticalsSerina Therapeutics For additional details, please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html Other Recent OfferingsGlobal Autoinjectors Market (3rd Edition), 2020-2030Prefilled Syringes Market (5th Edition), 2020-2030Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030Large Volume Wearable Injectors Market (4th Edition), 2018-2030  About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]
To order this detailed 310+ page report, please visit this link  Key Inclusions A detailed assessment of the current market landscape of therapeutics targeting STING pathway, based on several parameters, such as type of STING modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, biologics and others), phase of development (discovery, preclinical and clinical), target therapeutic area(s), type of therapy (monotherapy and combination therapy), route of administration (intratumoral, intravenous and others), and line of treatment (last line, second line or greater and first line or greater).The chapter also features an analysis of the developer landscape (including information on year of establishment, company size, geography and most active players).Further the chapter includes an analysis on the clinical trials focused on STING, along with information on parameters, such as recruitment status, study design and clinical endpoints.A detailed chapter highlighting various technology platforms that are being actively used for the development of STING modulators and analysis based on several parameters, such as type of modulator (agonist or antagonist), type of molecule (small molecules, cyclic dinucleotides, non-nucleotides, live biotherapeutics, nanoparticles and synthetic peptides), and analysis based on technology developer landscape (including information on year of establishment, company size and geography).Elaborate profiles of key players that are engaged in the development of therapeutics targeting STING pathway (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, recent developments and an informed future outlook.Additionally, each drug profile features information on the type of drug, route of administration, target indications and current status of development.Tabulated profiles of industry players (shortlisted on the basis of the antagonist in pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, key members of the executive team and recent developments), along with descriptions of their respective drug candidates.A study on various grants that have been awarded to research institutes engaged in projects related to STING pathway, during the period 2015 - Q1 2020, based on multiple parameters, such as number of grants awarded, amount awarded, funding institute, support period, funding mechanism, type of grant application, grant activity code, most popular NIH department, type of recipient organization, regional distribution, most popular recipient organization(s), prominent project leader(s) and study section.It also includes an analysis of on grant attractiveness.An analysis of big pharma players engaged in the development of therapeutics targeting STING pathway, based on several parameters, such as portfolio diversity, type of molecule, phase of development, therapeutic area(s), type of therapy and route of administration.In addition, the chapter features a benchmarking analysis of the aforementioned players.An analysis of the start-ups / small players (established in the last ten years, less than 50 employees) engaged in the development of therapeutics targeting STING pathway, based on several relevant parameters, such as portfolio diversity, type of molecule, phase of development, therapeutic area, funding received, number of investors, type of funding, partnership activity, number of patents filed, grants received, and start-up health indexing.A detailed publication analysis of more than 300 peer-reviewed, scientific articles that have been published during the period 2019 - Q1 2020, highlighting the research focus within the industry.
 In recent years, the concept of STING pathway targeting therapeutics has generated a lot of enthusiasm within the medical science community.The growing popularity of this therapeutic technique has not only garnered the interest of several medical researchers (reflected in the increasing volume of scientific literature (1,000+ articles published since 2015) on this subject), but also industry stakeholders focused on drug development (evident in the growing number of clinical trials and the grants awarded for STING focused projects in the recent past).To order this 310+ page report, which features 170+ figures and 200+ tables, please visit this link The USD 2.8 billion (by 2030) financial opportunity within the STING pathway targeting technologies market has been analysed across the following segments:Types of PaymentUpfront PaymentsMilestone Payments Type of STING ModulatorAgonistAntagonist Key Therapeutic Area(s)Oncological DisordersInflammatory DisordersInfectious DiseasesOthers Route of AdministrationIntratumoralIntravenousOralSubcutaneousOthers Type of MoleculeNon-nucleotideCyclic DinucleotideLive BiotherapeuticsOncolytic PeptidesSynthetic PeptidesOthers Key Geographical RegionsNorth AmericaEuropeAsia-Pacific  The STING Pathway targeting Therapeutics and Technologies, 2020-2030 report features the following companies, which we identified to be key players in this domain: Aduro BiotechBristol Myers SquibbEisaiGlaxoSmithKlineImmuneSensor TherapeuticsMerckNoxopharmSpring Bank PharmaceuticalsSynlogic Table of Contents  Preface 2.Executive Summary Introduction STING Pathway Targeting Therapeutics: Current Market Landscape STING Pathway Targeting Technologies: Current Market landscape Company Profiles Academic Grant Analysis STING Related Initiatives of Big Pharmaceutical Players Start-up Health Indexing Publication Analysis Partnerships and Collaborations Funding and Investment Analysis Market Sizing and Opportunity Analysis Executive Insights  Concluding Remarks  Appendix 1: Tabulated Data  Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html Contact DetailsGaurav Chaudhary+1 (415) 800 3415gaurav.chaudha[email protected]  
Roots Analysis has done a detailed study on STING Pathway targeting therapeutics and Technologies, 2020-2030, covering key aspects of the industry and identifying future growth opportunities.To order this 310+ page report, which features 150+ figures and 200+ tables, please visit this link Key Market Insights Many small / macro molecule-based STING pathway modulators are currently being evaluated as monotherapies as well as in combination with other drugsThe pipeline features candidates targeting different therapeutic areas and designed for administration through a variety of routes; majority of such therapeutics are being developed as third-line and second-line treatmentsIn recent years, several well funded start-ups have entered this field of research, and are gradually developing proprietary products based on the STING pathway for the treatment of a variety of indicationsIn addition, a number of big pharmaceutical players have also partnered with developers focused on STING targeting molecules in order to expand their respective capabilities in this upcoming field of pharmacologyPublished scientific literature indicates that both industry and academic players have made equal contributions to the innovation in this field; the major focus of such studies is presently on anti-cancer therapeuticsSeveral non-profit organizations have extended financial support to aid research efforts in this domain; the current focus appears to be on drug development and disease modelling studiesForeseeing a lucrative future, private and public investors have invested capital worth over USD 2.5 billion, across more than 80 instances, in companies involved in STING pathway researchThe rising interest is also reflected in recent partnership activity, involving the active participation of both international and indigenous companies; majority of the deals have been focused on novel technology platformsMultiple companies are developing novel technology platforms for enhancing the research and development of STING pathway targeting therapeuticsTechnology developers are expected to continue relying on licensing agreements involving different STING modulators as their primary source of revenues in the foreseen future For more information, please visit https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html Table of Contents  PREFACE1.1.Analysis by Number of Grants7.3.2.Analysis by Type of Recipient Organization7.3.10          Regional Distribution of Grant Recipients7.3.11          Most Popular Recipient Organizations: Analysis by Number of Grants and Amount Invested7.3.12.Analysis by Type of Publication10.3.2.Global STING Pathway Targeting Technologies Market, 2020-203013.3.1.
Roots Analysis has done a detailed study on STING Pathway targeting therapeutics and Technologies, 2020-2030, covering key aspects of the industry and identifying future growth opportunities.To order this 310+ page report, which features 150+ figures and 200+ tables, please visit this link Key Market Insights Many small / macro molecule-based STING pathway modulators are currently being evaluated as monotherapies as well as in combination with other drugsThe pipeline features candidates targeting different therapeutic areas and designed for administration through a variety of routes; majority of such therapeutics are being developed as third-line and second-line treatmentsIn recent years, several well funded start-ups have entered this field of research, and are gradually developing proprietary products based on the STING pathway for the treatment of a variety of indicationsIn addition, a number of big pharmaceutical players have also partnered with developers focused on STING targeting molecules in order to expand their respective capabilities in this upcoming field of pharmacologyPublished scientific literature indicates that both industry and academic players have made equal contributions to the innovation in this field; the major focus of such studies is presently on anti-cancer therapeuticsSeveral non-profit organizations have extended financial support to aid research efforts in this domain; the current focus appears to be on drug development and disease modelling studiesForeseeing a lucrative future, private and public investors have invested capital worth over USD 2.5 billion, across more than 80 instances, in companies involved in STING pathway researchThe rising interest is also reflected in recent partnership activity, involving the active participation of both international and indigenous companies; majority of the deals have been focused on novel technology platformsMultiple companies are developing novel technology platforms for enhancing the research and development of STING pathway targeting therapeuticsTechnology developers are expected to continue relying on licensing agreements involving different STING modulators as their primary source of revenues in the foreseen future For more information, please visit https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html Table of Contents  PREFACE1.1.Analysis by Number of Grants7.3.2.Analysis by Type of Recipient Organization7.3.10          Regional Distribution of Grant Recipients7.3.11          Most Popular Recipient Organizations: Analysis by Number of Grants and Amount Invested7.3.12.Analysis by Type of Publication10.3.2.Global STING Pathway Targeting Technologies Market, 2020-203013.3.1.
STING, having generated significant interest within the medical research community, is currently considered one of the fastest growing areas of cancer immunotherapy and is being pursued by several large pharmaceutical companies Roots Analysis is pleased to announce the publication of its recent study, titled, “STING Pathway Targeting Therapeutics and Technologies, 2020-2030.” The report features an extensive study of the current market landscape and future potential of these therapeutics and affiliated technologies, over the next decade.This study focuses specifically on small molecule STING modulators.The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.In addition to other elements, the study includes:A detailed assessment of the current market landscape of therapeutics targeting STING Pathway.A detailed assessment of the current market landscape of various technology platforms that are being actively used for the development of STING modulators.Detailed profiles of developers of therapeutics targeting STING pathway (shortlisted on the basis of phase of development of pipeline products).An in-depth analysis of more than 280 grants that have been awarded to research institutes engaged in STING pathway targeting therapeutics-related projects.An analysis of the initiatives of big pharma players engaged in this domain.An analysis of the start-ups / small players (established in the last ten years, less than 50 employees) engaged in the development of STING pathway targeting therapeutics.A detailed publication analysis of more than 300 peer-reviewed, scientific articles that have been published during the period 2019 - Q1 2020.An analysis of the partnerships that have been established in this domain, in the recent past.An analysis of the investments made in this domain.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Types of PaymentUpfront PaymentsMilestone Payments Type of STING ModulatorAgonistAntagonist Key Therapeutic Area(s)Oncological DisordersInflammatory DisordersInfectious DiseasesOthers Route of AdministrationIntratumoralIntravenousOralSubcutaneousOthers Type of MoleculeNon-nucleotideCyclic DinucleotideLive BiotherapeuticsOncolytic PeptidesSynthetic PeptidesOthers Key Geographical RegionsNorth AmericaEuropeAsia-Pacific Key companies covered in the reportAduro BiotechBristol Myers SquibbEisaiGlaxoSmithKlineImmuneSensor TherapeuticsMerckNoxopharmSpring Bank PharmaceuticalsSynlogic For more information please click on the following link:https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html Other Recent OfferingsNuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030Global Psychedelic Therapeutics Market by Type of Psychedelic Substance (Ketamine, Psilocybin, MDMA and Others), by Origin (Natural and Synthetic), by Type of Therapy (Monotherapy, Combination and Others), by Route of Administration (Oral, Intravenous, Intranasal and Others) and by Key Geographies (North America, Europe and Asia- Pacific and rest of the world): Industry Trends and Global Forecasts, 2020-2030Endocannabinoid System Targeted Therapeutics Market, 2020-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
The latest trending report Global CROCIN Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 offered by DecisionDatabases.com is an informative study covering the market with detailed analysis.The report will assist reader with better understanding and decision making.The CROCIN market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.The global CROCIN market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx%% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.Final Report will cover the impact of COVID-19 on this industry.Browse the complete report and table of contents @ https://www.decisiondatabases.com/ip/13008-crocin-industry-analysis-reportThe major players covered in CROCIN are: TCI Merck Target molecule Corp. Carbosynth Cayman WILSHIRE APExBIOBy Type, CROCIN market has been segmented into Purity>98% Purity) Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)Download Free Sample Report of Global CROCIN Market @ https://www.decisiondatabases.com/contact/download-sample-13008The content of the study subjects, includes a total of 15 chapters:Chapter 1, to describe CROCIN product scope, market overview, market opportunities, market driving force and market risks.Chapter 2, to profile the top manufacturers of CROCIN, with price, sales, revenue and global market share of CROCIN in 2018 and 2019.Chapter 3, the CROCIN competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.Chapter 4, the CROCIN breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.Chapter 12, CROCIN market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.Chapter 13, 14 and 15, to describe CROCIN sales channel, distributors, customers, research findings and conclusion, appendix and data source.Purchase the complete Global CROCIN Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-13008Other Reports by DecisionDatabases.com:Global COVID-19 Medicine Market 2020 by Company, Regions, Type and Application, Forecast to 2025Global Anthrax Vaccines Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Global Covid-19 Vaccine Market 2020 by Company, Regions, Type and Application, Forecast to 2025About-Us:DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics.DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors.We provide intellectual, precise and meaningful data at a lightning speed.CROCINMarketFor more details:DecisionDatabases.comE-Mail: [email protected]: +91 9028057900Web: https://www.decisiondatabases.com/News Source: https://www.industrynewsengine.com/2021/01/05/crocin-market-report-till-2025-global-manufacturers-analysis/
The latest trending report Global Dirithromycin Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 offered by DecisionDatabases.com is an informative study covering the market with detailed analysis.The report will assist reader with better understanding and decision making.The Dirithromycin market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.The global Dirithromycin market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx%% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.Final Report will cover the impact of COVID-19 on this industry.Browse the complete report and table of contents @ https://www.decisiondatabases.com/ip/13010-dirithromycin-industry-analysis-reportThe major players covered in Dirithromycin are: Chem Reagents Boc Sciences Target Molecule Corp TCI Merck MedChemexpress Toronto Research Chemicals Cayman Cato Research Chemicals CHEMOSBy Type, Dirithromycin market has been segmented into Purity>98% Purity) Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)Download Free Sample Report of Global Dirithromycin Market @ https://www.decisiondatabases.com/contact/download-sample-13010The content of the study subjects, includes a total of 15 chapters:Chapter 1, to describe Dirithromycin product scope, market overview, market opportunities, market driving force and market risks.Chapter 2, to profile the top manufacturers of Dirithromycin, with price, sales, revenue and global market share of Dirithromycin in 2018 and 2019.Chapter 3, the Dirithromycin competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.Chapter 4, the Dirithromycin breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.Chapter 12, Dirithromycin market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.Chapter 13, 14 and 15, to describe Dirithromycin sales channel, distributors, customers, research findings and conclusion, appendix and data source.Purchase the complete Global Dirithromycin Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-13010Other Reports by DecisionDatabases.com:Global Bleomycin Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Global Dactinomycin Market 2020 by Company, Regions, Type and Application, Forecast to 2025Global Mitomycin Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025About-Us:DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics.DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors.We provide intellectual, precise and meaningful data at a lightning speed.For more details:DecisionDatabases.comE-Mail: [email protected]: +91 9028057900Web: https://www.decisiondatabases.com/News Source: https://www.industrynewsengine.com/2021/01/05/dirithromycin-market-report-till-2025-global-manufacturers-analysis/
The latest trending report Global Propafenone Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 offered by DecisionDatabases.com is an informative study covering the market with detailed analysis.The report will assist reader with better understanding and decision making.The Propafenone market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.The global Propafenone market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx%% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.Final Report will cover the impact of COVID-19 on this industry.Browse the complete report and table of contents @ https://www.decisiondatabases.com/ip/13196-propafenone-industry-analysis-reportThe major players covered in Propafenone are: Target Molecule TCI CarBomer QUALITY CONTROL CHEMICALS Alfa-Chemistry Cato Research Chemicals UHN Shanghai Pubchem CHEMOS Boc SciencesBy Type, Propafenone market has been segmented into Purity>99% Purity) Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)Download Free Sample Report of Global Propafenone Market @ https://www.decisiondatabases.com/contact/download-sample-13196The content of the study subjects, includes a total of 15 chapters:Chapter 1, to describe Propafenone product scope, market overview, market opportunities, market driving force and market risks.Chapter 2, to profile the top manufacturers of Propafenone, with price, sales, revenue and global market share of Propafenone in 2018 and 2019.Chapter 3, the Propafenone competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.Chapter 4, the Propafenone breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.Chapter 12, Propafenone market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.Chapter 13, 14 and 15, to describe Propafenone sales channel, distributors, customers, research findings and conclusion, appendix and data source.Purchase the complete Global Propafenone Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-13196Other Reports by DecisionDatabases.com:Global Xenon Lights Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Global Propane Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Global Trimethylol Propane Dially Ether (TMPDE) Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025About-Us:DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics.DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors.We provide intellectual, precise and meaningful data at a lightning speed.For more details:DecisionDatabases.comE-Mail: [email protected]: +91 9028057900Web: https://www.decisiondatabases.com/News Source – https://www.industrynewsengine.com/2021/01/05/global-propafenone-market-2020-covid-19-impact-analysis-report-2025/
The latest trending report Global Esculin Hydrate Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 offered by DecisionDatabases.com is an informative study covering the market with detailed analysis.The report will assist reader with better understanding and decision making.The Esculin Hydrate market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.The global Esculin Hydrate market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx%% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.Final Report will cover the impact of COVID-19 on this industry.Browse the complete report and table of contents @ https://www.decisiondatabases.com/ip/13332-esculin-hydrate-industry-analysis-reportThe major players covered in Esculin Hydrate are: CFMOT-PHYTO BOC Sciences TCI AMERICA Service Chemical Target Molecule Corp Extrasynthese Discovery Fine Chemicals EMMX Biotechnology AdooQ BioScience City Chemical BIOSYNTHBy Type, Esculin Hydrate market has been segmented into Purity>99% Purity ) Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)Download Free Sample Report of Global Esculin Hydrate Market @ https://www.decisiondatabases.com/contact/download-sample-13332The content of the study subjects, includes a total of 15 chapters:Chapter 1, to describe Esculin Hydrate product scope, market overview, market opportunities, market driving force and market risks.Chapter 2, to profile the top manufacturers of Esculin Hydrate, with price, sales, revenue and global market share of Esculin Hydrate in 2018 and 2019.Chapter 3, the Esculin Hydrate competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.Chapter 4, the Esculin Hydrate breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.Chapter 12, Esculin Hydrate market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.Chapter 13, 14 and 15, to describe Esculin Hydrate sales channel, distributors, customers, research findings and conclusion, appendix and data source.Purchase the complete Global Esculin Hydrate Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-13332Other Reports by DecisionDatabases.com:Global Salt Hydrate Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Global Dextrose Monohydrate Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Global Alumina Trihydrate (ATH) Flame Retardant Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025About-Us:DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics.DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors.We provide intellectual, precise and meaningful data at a lightning speed.For more details:DecisionDatabases.comE-Mail: [email protected]: +91 9028057900Web: https://www.decisiondatabases.com/News Source – https://www.industrynewsengine.com/2021/01/05/global-esculin-hydrate-market-2020-industry-analysis-and-forecast-2025/
The latest trending report Global Betaxolol Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 offered by DecisionDatabases.com is an informative study covering the market with detailed analysis.The report will assist reader with better understanding and decision making.The Betaxolol market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.The global Betaxolol market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx%% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.Final Report will cover the impact of COVID-19 on this industry.Browse the complete report and table of contents @ https://www.decisiondatabases.com/ip/13267-betaxolol-industry-analysis-reportThe major players covered in Betaxolol are: MedChemexpress Service Chemical BOC Sciences AdooQ BioScience Trc-Canada Target molecule Corp Carbone Scientific Alfa Chemistry APAC Pharmaceutical Carbosynth J ChemicalBy Type, Betaxolol market has been segmented into Liquid Tablet OthersBy Application, Betaxolol has been segmented into:  Pharmaceutical intermediates Chemical intermediate OthersThe report offers in-depth assessment of the growth and other aspects of the Betaxolol market in important countries (regions), including: North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America (Brazil, Argentina, etc.) Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)Download Free Sample Report of Global Betaxolol Market @ https://www.decisiondatabases.com/contact/download-sample-13267The content of the study subjects, includes a total of 15 chapters:Chapter 1, to describe Betaxolol product scope, market overview, market opportunities, market driving force and market risks.Chapter 2, to profile the top manufacturers of Betaxolol, with price, sales, revenue and global market share of Betaxolol in 2018 and 2019.Chapter 3, the Betaxolol competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.Chapter 4, the Betaxolol breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.Chapter 12, Betaxolol market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.Chapter 13, 14 and 15, to describe Betaxolol sales channel, distributors, customers, research findings and conclusion, appendix and data source.Purchase the complete Global Betaxolol Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-13267Other Reports by DecisionDatabases.com:Global Liquid Roofing Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Global Liquid Encapsulation Materials Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025Global Liquid Applied Membrane Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025About-Us:DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics.DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors.We provide intellectual, precise and meaningful data at a lightning speed.For more details:DecisionDatabases.comE-Mail: [email protected]: +91 9028057900Web: https://www.decisiondatabases.com/News Source – https://www.industrynewsengine.com/2021/01/05/global-betaxolol-market-2020-industry-analysis-and-forecast-2025/
More

Top